Moat.
Speed.
Allocation.
The platform moat that survives 2028 is being chosen this year.
This briefing tells you which platform moats survive 2028 in pharma sales as AI rewrites build economics. Read it before your R&D allocation locks for the decade.
The 10-page briefing. Worth 20 minutes.
One email. One PDF. Worth twenty minutes of your week.
We send it once. Work emails only.
Tuesday 10:40, affiliate Digital Steering. Rep adoption of Veeva's Pre-call Agent at seventy-three percent. MLR cycle time down to thirty-six hours on standard content, still forty-eight on Medical Affairs. Your phone buzzes. Email from the Regional Digital Director: "Global is bringing the CAIO hire in front of the executive committee Thursday. Standardisation recommendation on commercial-AI across affiliates." Your Veeva account manager has a Q3 AI module expansion proposal on your desk. Your Salesforce Life Sciences migration is eighteen months into a twenty-four-month runway.
You are not running one commercial-AI stack. You are running two, and only one is on your scorecard. One funds what Veeva, Salesforce, and IQVIA sell back cheaper through more copilot seats. The other funds what has to exist by 2028: the HCP interaction corpus you have not captured, the consent-scope graph you have not drawn, the integration depth that outlasts three model swaps.
The moat that matters in 2028 is not inside the vendor AI module. It is underneath it.
This is the question your GM is about to be asked by Global. The briefing below is what you want in your hand before the CAIO deck lands.
Build Velocity. Product Defensibility. Capital Allocation.
Three questions every commercial CTO at a mid-sized European pharma affiliate is tracking. The third is the crux. The first two are how you earn the right to answer it.
Is our commercial-tech speed shipping validated work, or demos the Medical Director rejects?
Pre-call Agent adoption at seventy percent. MLR cycle on Medical Affairs content flat. Pharmacovigilance validation slipping on agent intake. Veeva, Salesforce, and IQVIA ship AI on their release cycle, not yours. Buy what the vendor layer can carry. Own the validation discipline.
What does our commercial-tech do that the vendor AI module cannot copy for every affiliate?
Your Pre-call summary is on a vendor upgrade cycle. Your HCP interaction corpus, consent-scope graph, and MSL-to-KOL chain compound. The reasoning sits in three senior commercial-ops people, and two of them had recruiter calls last month.
Is our commercial-AI budget one instrument or two?
One funds the Veeva, Salesforce, and IQVIA stack cheaper. The other builds the 2028 HCP data-and-consent-graph moat. On one licence hurdle the first wins every quarter. On one scorecard the second does not exist.
What you get when you download
An 11-page report for commercial CTOs, Heads of Commercial Technology, and VPs Commercial Platforms at mid-sized European pharma affiliates. Designed to be read in one sitting before your next commercial-tech review.
Your industry, your commercial-tech function, and why they are one problem
What is happening to European pharma commercialisation: vendor AI modules landing on every affiliate's SG&A page on the same upgrade cycle, grounded on cross-affiliate aggregated data. What is happening inside your commercial-tech: Pre-call Agent adoption up, MLR cycle on Medical Affairs flat, validation pressure rising. And the intersection: same force, two altitudes, one problem.
Four moves across build engine, platform and data, product thesis, and platform bench
Instrument validation depth on agent-generated Medical Affairs content, not just MLR cycle time. Build the moat underneath the vendor layer through HCP interaction corpus, consent-scope graph, and integration depth. Author the vendor-vs-affiliate boundary before the CAIO deck does. Rebuild the junior pathway around senior and agent pairing.
Five questions for your next commercial-tech review
Is your commercial-AI budget one instrument or two, and what is the kill criterion on each? What grounds the Pre-call Agent summary your reps use? How many months to reconstruct HCP identity and consent-scope reasoning if your MDM lead leaves? Where did the freed hours from seventy-percent Pre-call adoption go? Is your Q1 boundary agreement with the GM written?
Calibrated for each seat at the table.